HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Advanced aggressive fibromatosis: Effective palliation with chemotherapy.

AbstractBACKGROUND:
Aggressive fibromatosis (AF) is a locally invasive proliferative disease. The mainstay of treatment is surgery. Chemotherapy may be considered in inoperable AF following failure of hormonal therapy and/or NSAIDs.
MATERIAL AND METHODS:
We conducted a retrospective search of the prospectively maintained Royal Marsden Hospital Sarcoma Unit database to identify patients with AF treated with chemotherapy between 1987 and 2009.
RESULTS:
Thirty-nine patients, thirty one females and eight males, received one or more lines of chemotherapy. The most frequently employed chemotherapy regimens were methotrexate/vinblastine [MTX/VBL] (18) and pegylated liposomal doxorubicin [PLD] (14). MTX/VBL was administered weekly or every two weeks at MTX 50 mg and VBL 10 mg. Treatment duration ranged from three weeks to one year with a median of 4.5 months. Partial response (PR) was observed in 11% of cases, disease stabilisation (SD) in 60% and progressive disease (PD) in 22%. Time to progression ranged from one month to sixteen years. The main toxicities reported were mucositis (4), peripheral neuropathy (3), vomiting (3), and neutropenia (3). PLD was administered at 40-50 mg/m(2) every four weeks, for up to six cycles. PR was achieved in 33% and in the remainder the disease was stable with no progression during treatment. Three (25%) patients have so far progressed after treatment. Symptomatic benefit, especially pain relief, was reported in 86% (12/14) of cases. Main toxicities included palmar plantar erythema (5) and mucositis (4).
DISCUSSION:
MTX/VBL remains a useful combination but PLD is emerging as a well tolerated and effective systemic therapy in advanced AF.
AuthorsAnastasia Constantinidou, Robin L Jones, Michelle Scurr, Omar Al-Muderis, Ian Judson
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 50 Issue 3 Pg. 455-61 (Apr 2011) ISSN: 1651-226X [Electronic] England
PMID20799916 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • liposomal doxorubicin
  • Polyethylene Glycols
  • Vinblastine
  • Doxorubicin
  • Methotrexate
Topics
  • Abdominal Neoplasms (diagnostic imaging, drug therapy, pathology)
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Child
  • Child, Preschool
  • Disease Progression
  • Doxorubicin (administration & dosage, analogs & derivatives)
  • Female
  • Fibromatosis, Aggressive (diagnostic imaging, drug therapy, pathology)
  • Humans
  • Male
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Neoplasm Invasiveness
  • Palliative Care (methods)
  • Polyethylene Glycols (administration & dosage)
  • Radiography
  • Registries (statistics & numerical data)
  • Retrospective Studies
  • Treatment Outcome
  • Vinblastine (administration & dosage)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: